AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
The company posted a net profit of ₹1.9 billion for FY26, supported by 11 new regulatory approvals and a dividend recommendation of ₹36 per share.
— 2 earlier stories on Astrazeneca Pharma India Ltd. →What's new
- Revenue rose 33% to ₹22.8 billion.
- Net profit grew to ₹1.9 billion from ₹1.2 billion.
- The company secured 11 regulatory approvals, including its first rare disease therapy, Eculizumab.
Why this matters
AstraZeneca is converting its pipeline into top-line growth through label expansions for established oncology drugs. The 62% profit jump confirms these new indications scale efficiently.
What we're watching
- Whether the pace of new drug approvals continues in FY27.
- Shareholder response to the proposed ₹36 dividend.
- Contribution of the new rare disease portfolio to margins.
The full read
AstraZeneca Pharma India closed FY26 with ₹22.8 billion in revenue, a 33% increase over the prior year. Profit after tax reached ₹1.9 billion, up from the ₹1.2 billion reported in FY25. The company’s performance relies on its oncology and biopharmaceuticals pipeline, which secured 11 regulatory approvals during the year. These include new indications for Durvalumab, Osimertinib, and Trastuzumab deruxtecan. The company also entered the rare disease market with the launch of Eculizumab.
Growth is accelerating.
The board recommended a final dividend of ₹36 per share, pending shareholder approval. The company is using its existing drug portfolio to capture new market segments, maintaining a strong growth momentum without relying on a single product. The next test is whether the company can maintain this approval pace in the coming year.
Questions answered
- What drove the revenue growth for the year?
- Growth came from the oncology and biopharmaceuticals segments. The company expanded the market reach of drugs like Durvalumab and Osimertinib through new regulatory approvals.
- How did net profit compare to the previous year?
- Net profit rose to ₹1.9 billion from ₹1.2 billion in the prior year.
- What is the status of the dividend?
- The board recommended a final dividend of ₹36 per share. This remains subject to shareholder approval.
- Did the company enter any new therapeutic areas?
- Yes. It launched its first rare disease therapy, Eculizumab, as part of its 11 regulatory approvals during the year.
Story so far
All notes on ASTRAZEN →- 26 May 2026 · 7:50 PM IST AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
- today AstraZeneca Pharma India profit rises to ₹1.9 billion
- 6d ago AstraZeneca India wins CDSCO nod for Calquence in MCL